Form 8-K

8-K — HeartSciences Inc.

Accession: 0001213900-26-100185

Filed: 2026-09-15

Period: 2026-09-15

CIK: 0001468492

SIC: 6199 (FINANCE SERVICES)

Item: Results of Operations and Financial Condition

Item: Financial Statements and Exhibits

Documents

8-K — ea0305626-8k_heart.htm (Primary)

EX-99.1 — PRESS RELEASE DATED SEPTEMBER 15, 2026 (ea030562601ex99-1.htm)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K — CURRENT REPORT

8-K (Primary)

Filename: ea0305626-8k_heart.htm · Sequence: 1

false

0001468492

2026-09-15

0001468492

us-gaap:CommonStockMember

2026-09-15

0001468492

HSCSW:WarrantsMember

2026-09-15

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities

Exchange Act of 1934

Date of Report (Date of earliest

event reported): September 15, 2026

HEARTSCIENCES INC.

(Exact name of Registrant as Specified in Its

Charter)

Texas

001-41422

26-1344466

(State or Other Jurisdiction

of Incorporation)

(Commission File Number)

(IRS Employer

Identification No.)

550 Reserve Street, Suite 360

Southlake, Texas

76092

(Address of Principal Executive Offices)

(Zip Code)

Registrant’s Telephone Number, Including Area Code: 682 237-7781

n/a

(Former Name or Former Address, if Changed Since

Last Report)

Check the appropriate box below if the Form 8-K filing is intended

to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities

Act (17 CFR 230.425)

☒ Soliciting material pursuant to Rule 14a-12 under the Exchange

Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under

the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under

the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b)

of the Act:

Title of each class

Trading

Symbol(s)

Name of each exchange on which

registered

Common Stock

HSCS

The Nasdaq Stock Market LLC

Warrants

HSCSW

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth

company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange

Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant

has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant

to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On September 15, 2026, HeartSciences

Inc. (“HeartSciences” or the “Company”) issued a press release providing information regarding certain of the

Company’s financial and operating results for the quarter ended July 31, 2026, and other business updates, including with respect

to the Proposed Transaction (as defined below).

As previously reported,

on June 23, 2026, Fortitude Mining Holdings, Inc. (“Fortitude”), a vertically-integrated digital asset mining platform anchored

in Zcash, and HeartSciences entered into a definitive merger agreement to combine in an all-stock transaction (the “Proposed Transaction”).

The information provided

in this Item 2.02 of this Current Report on Form 8-K (this “Current Report”), including Exhibit 99.1 attached hereto and incorporated

by reference herein, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Exchange Act of

1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. Such information shall not

be deemed incorporated by reference into any filing of HeartSciences under the Securities Act of 1933, as amended (the “Securities

Act”), or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such

filing, except as otherwise expressly set forth by specific reference in such filing.

The

following is important information that should be read together with the information included herein.

Additional Information

and Where to Find It

The

information provided in Item 2.02 of this Current Report, including Exhibit 99.1 attached hereto, related to each of Fortitude and HeartSciences,

their respective businesses and the Proposed Transaction may be deemed solicitation material in respect of the Proposed Transaction. In

connection with the Proposed Transaction, HeartSciences has filed a preliminary proxy statement on Schedule 14A with the U.S. Securities

and Exchange Commission (“SEC”) on July 27, 2026 and may file additional relevant materials with the SEC. Following the filing

of a definitive proxy statement with the SEC, HeartSciences will mail the definitive proxy statement and a proxy card to each shareholder

entitled to vote at the special meeting relating to the Proposed Transaction. INVESTORS AND SHAREHOLDERS OF HEARTSCIENCES ARE URGED TO

READ THESE MATERIALS (INCLUDING ANY AMENDMENTS OR SUPPLEMENTS THERETO) AND ANY OTHER RELEVANT DOCUMENTS IN CONNECTION WITH THE PROPOSED

TRANSACTION THAT HEARTSCIENCES HAS FILED OR MAY FILE WITH THE SEC WHEN THEY BECOME AVAILABLE BECAUSE THEY CONTAIN IMPORTANT INFORMATION

ABOUT HEARTSCIENCES AND THE PROPOSED TRANSACTION. COMMUNICATIONS THAT DO NOT CONTAIN ALL THE INFORMATION THAT SHOULD BE CONSIDERED CONCERNING

THE PROPOSED TRANSACTION AND RELATED MATTERS ARE NOT INTENDED TO PROVIDE THE BASIS FOR ANY INVESTMENT DECISION OR ANY OTHER DECISION IN

RESPECT OF SUCH MATTERS. The preliminary proxy statement, the definitive proxy statement and other relevant materials in connection with

the Proposed Transaction (when they become available), and any other documents filed by HeartSciences with the SEC, may be obtained free

of charge at the SEC’s website at www.sec.gov. In addition, investors and shareholders may obtain free copies of the documents filed

with the SEC or by sending a request to the HeartSciences Investor Relations Department at investorrelations@heartsciences.com.

Participants in the

Solicitation

HeartSciences and Fortitude,

their respective directors and executive officers, and certain executive officers of Digital Currency Group, Inc., the parent company

of Fortitude, may be deemed to be participants in the solicitation of proxies from HeartSciences’ shareholders with respect to the

Proposed Transaction. Information regarding the identity of the potential participants, and their direct or indirect interests in the

Proposed Transaction, by security holdings or otherwise, is set forth in the preliminary proxy statement and other materials filed or

that may be filed with the SEC in connection with the Proposed Transaction.

No Offer or Solicitation

Any information contained herein

is not intended to and does not constitute, or form part of, an offer, invitation or the solicitation of an offer or invitation to purchase,

otherwise acquire, subscribe for, sell or otherwise dispose of any securities, or the solicitation of any vote or approval in any jurisdiction,

pursuant to the Proposed Transaction or otherwise, nor shall there be any sale, issuance or transfer of securities in any jurisdiction

in contravention of applicable law. The Proposed Transaction will be implemented solely pursuant to the terms and conditions of the merger

agreement, which contain the full terms and conditions of the Proposed Transaction.

Item 9.01 Financial Statements and Exhibits.

Exhibit No.

Description

99.1*

Press Release dated September 15, 2026

Exhibit 104*

Cover Page Interactive Data File (embedded within the Inline XBRL document).

* Furnished herewith.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934,

the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

HEARTSCIENCES INC.

Date: September 15, 2026

By:

/s/ Andrew Simpson

Name:

Andrew Simpson

Title:

President, Chief Executive Officer and Chairman of the Board of Directors

EX-99.1 — PRESS RELEASE DATED SEPTEMBER 15, 2026

EX-99.1

Filename: ea030562601ex99-1.htm · Sequence: 2

Exhibit 99.1

HeartSciences Reports Fiscal First Quarter 2027 Financial Results

and Provides Business Update

Proposed business combination with Fortitude, a vertically-integrated

digital asset mining platform anchored in Zcash, continues to progress, with closing expected in Q4 calendar 2026

Commercial effort concentrated on the MyoVista Insights™ platform,

with first US commercial agreements signed and selection as the AI-ECG delivery platform for a major European reference center

Southlake, TX, September 15, 2026 (GLOBE NEWSWIRE) -- HeartSciences

Inc. (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”), a healthcare information technology (“HIT”)

company focused on advancing electrocardiography (“ECG” or “EKG”) through the integration of artificial intelligence

(“AI”), today reported financial results for its fiscal first quarter ended July 31, 2026 (“FQ1 2027”) and provided

a business update.

Proposed Transaction with Fortitude

The proposed business combination with Fortitude Mining Holdings, Inc.

(“Fortitude”), announced in June 2026 (the “Proposed Transaction”), continues to progress. The Company expects

to close the Proposed Transaction in Q4 calendar 2026, subject to customary closing conditions, including approval by HeartSciences’

shareholders.

Fortitude is a meaningful part of the Zcash ecosystem and, in our view,

Zcash has been among the best-performing large capitalization digital assets over the past year and is attracting growing institutional

interest.

Since announcement of the Proposed Transaction, Fortitude has reported

a number of developments, including:

● Execution of a purchase agreement for 9,000 Z15 Pro miners, representing approximately 7.5 Gsol/s of Zcash mining capacity;

● Energization of its 12 MW facility in Grand Island, Nebraska; and

● Acquisition of a 12.5 MW facility in Prosser, Nebraska.

In August 2026, Fortitude subscribed for approximately $1.0 million

of shares of HeartSciences’ common stock. The exchange ratio under the merger agreement between Fortitude and the Company was not

adjusted as a result, and no additional shares will be issued to Fortitude at closing in respect of the amount invested.

MyoVista Insights

HeartSciences has continued to concentrate its commercial effort on

MyoVista Insights, a device-agnostic ECG management and AI orchestration platform that works with the ECG hardware hospitals already own.

Progress in the period and since includes:

● First US commercial agreements signed following full launch;

● Availability of the first third-party FDA-cleared AI-ECG algorithm through the AI-ECG algorithm marketplace, with the platform now

at version 1.4 following further upgrades since launch;

● Selection of MyoVista Insights as the ECG management and AI-ECG delivery platform for a clinical program at a major European reference

center, which is anticipated to extend into a larger multicenter project;

● Launch of a new corporate website built around MyoVista Insights, giving the healthcare industry and its wider stakeholders a much

clearer account of the platform’s purpose, functionality, interoperability and benefits, and of how the AI-ECG marketplace is designed

to deliver algorithms directly into clinical workflows; and

● Continued expansion of the patent portfolio, including the grant of a European patent for ECG-based assessment of diastolic function,

taking the portfolio to more than 45 granted patents.

The Company’s resources continue to be directed primarily to

MyoVista Insights. Feedback from clinicians and health systems has been consistently positive, and our priorities are growing revenue,

building relationships with key reference centers, and expanding the number of algorithms available through the AI-ECG marketplace.

The FDA 510(k) submission for the MyoVista wavECG device remains under

FDA review. However, as previously set out, that submission does not include the AI algorithm necessary for commercialization, which would

require significant additional research and development, regulatory and commercialization expenditure over an uncertain timeline and is

onerous relative to the software platform. It is also apparent that the emergence of cloud-based AI-ECG algorithms reduces the commercial

rationale for a proprietary device with embedded algorithms. These considerations apply irrespective of the outcome of the pending 510(k)

review and a probable timeline to commercialization cannot currently be established. Accordingly, the Company has recorded a reserve of

$0.3 million against the remaining carrying value of the related inventory and does not currently intend to commit significant additional

resources to commercialization of the device.

Management Commentary

“This has been a period of significant change for the Company.

The proposed combination with Fortitude is expected to give our shareholders exposure to a business that is a meaningful participant in

the Zcash ecosystem. In our view, it represents a significant opportunity for shareholders and the transaction continues to move toward

closing,” said Andrew Simpson, CEO of HeartSciences.

Mr. Simpson continued, “We believe MyoVista Insights™ offers

a best-in-class, cloud-native, vendor- and device-agnostic ECG management platform designed to modernize ECG workflows and enable scalable

deployment of AI-ECG capabilities across healthcare systems. The response from the clinicians using it has been excellent. We have signed

our first commercial agreements in the United States, we have been selected as the delivery platform for a clinical program at a leading

European reference center, and the AI-ECG marketplace is attracting developers that recognize it as a route to deliver their models directly

into clinical workflows at scale. We expect significant commercial progress in the year ahead and our efforts are focused on execution

and delivery.”

Fiscal First Quarter 2027 Financial Results

HeartSciences reported no meaningful revenue for FQ1 2027. The loss

from operations was $2.9 million (FQ1 2026: $1.9 million), which included an increase of approximately $0.5 million in legal and professional

costs associated with the Proposed Transaction, approximately $0.5 million of non-cash share-based compensation arising on the vesting

of equity awards following the passing of Mark Hilz, and the $0.3 million inventory reserve referred to above. The net loss for FQ1 2027

was $3.2 million (FQ1 2026: $2.1 million).

As of July 31, 2026, the Company had a shareholders’ deficit

of $2.0 million. Since the period end, the Company raised gross proceeds of approximately $1.0 million from a sale of its common stock

to Fortitude, raised net proceeds of approximately $1.2 million for sales made pursuant to the Company’s at-the-market facility,

and exchanged $200,000 of principal under an existing promissory note for shares of its common stock. The exchange ratio under the merger

agreement between Fortitude and the Company was not adjusted as a result of any of these issuances.

Complete financial results are included in the Company’s Quarterly

Report on Form 10-Q for the fiscal quarter ended July 31, 2026, which was filed with the U.S. Securities and Exchange Commission on September

14, 2026 and is available on the Company’s website at www.heartsciences.com.

About HeartSciences

HeartSciences is a healthcare information technology company advancing

the use of ECG/EKGs through the integration of artificial intelligence. HeartSciences’ MyoVista Insights™ Platform is a cloud-native,

vendor- and device-agnostic ECG management system designed to modernize ECG workflows and improve clinical efficiency and decision-making.

The platform’s AI-ECG marketplace is designed to deliver AI-ECG algorithms into clinical workflows across a health system’s

existing ECG equipment.

For more information, please visit www.heartsciences.com and follow

HeartSciences on X @HeartSciences.

About Fortitude

Fortitude, currently wholly-owned by DCG, is an institutional-scale,

vertically integrated venture mining platform operating across the Proof-of-Work ecosystem and anchored in Zcash. Fortitude pairs self-mining

operations with an owned data center footprint, a diversified power portfolio backed by competitive long-term contracts, and disciplined

capital allocation to identify and scale high-conviction opportunities in emerging Proof-of-Work ecosystems, beginning with its leadership

position in the Zcash network. Fortitude is led by an experienced team of operators, capital markets professionals, and digital asset

specialists with a track record of identifying and scaling high-conviction opportunities and building privacy-preserving digital asset

infrastructure.

For more information, visit www.fortitudemining.com and follow

Fortitude on X at @FortitudeCrypto

Cautionary Note Regarding Forward-Looking Information

This press release may contain forward-looking statements concerning

HeartSciences, Fortitude and the Proposed Transaction and other matters. These forward-looking statements generally can be identified

by the use of words such as “aim,” “anticipate,” “expect,” “plan,” “could,”

“may,” “will,” “believe,” “estimate,” “forecast,” “goal,” “project,”

“potential,” “target,” “objective,” “intend,” and other words of similar meaning, but

the absence of these words does not mean that a statement is not forward-looking. All statements HeartSciences and/or Fortitude make in

communications that do not relate to matters of historical fact should be considered forward-looking statements.

These forward-looking statements are based on management’s current

expectations and assumptions as of the date of such communication and are subject to a number of known and unknown risks, uncertainties,

and other factors that could cause actual results to differ materially from those expressed or implied by such statements, which may include,

without limitation, the following: the risk that the Proposed Transaction may not be completed on the anticipated timeline or at all;

the failure to satisfy the conditions to the closing of the Proposed Transaction, including obtaining the requisite approval of HeartSciences’

shareholders; market, macroeconomic, or other conditions that could adversely affect either HeartSciences or Fortitude, or the combined

company; risks related to the integration of the two companies and the management of a newly public company; risks relating to Fortitude’s

operations and business, including the highly volatile nature of the price of Zcash and other cryptocurrencies; risks relating to significant

legal, commercial, regulatory and technical uncertainty regarding digital assets generally; risks relating to the commercialization of

MyoVista Insights, including the rate of adoption by healthcare providers and the conversion of agreements into revenue; and risks relating

to the MyoVista wavECG device, including the timing and outcome of the pending FDA 510(k) submission and the recoverability of the related

inventory. Additional factors that may cause actual results to differ materially from those expressed or implied by the forward-looking

statements in this press release are discussed in HeartSciences’ preliminary proxy statement on Schedule 14A, filed with the SEC

on July 27, 2026 in connection with the Proposed Transaction, HeartSciences’ Annual Report on Form 10-K, filed with the SEC on July

23, 2026, HeartSciences’ Quarterly Report on Form 10-Q filed with the SEC on September 14, 2026, and its other reports filed with

the SEC from time to time. Readers are cautioned not to place undue reliance on these forward-looking statements. Each of HeartSciences

and Fortitude expressly disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information,

future events, or otherwise, except as required by applicable law. All forward-looking statements are made as of the date of this press

release.

Additional Information About the Proposed Transaction and Where

to Find It

This press release may be deemed solicitation material in respect of

the Proposed Transaction. In connection with the Proposed Transaction, HeartSciences filed a preliminary proxy statement on Schedule 14A

with the SEC on July 27, 2026 and may file additional relevant materials with the SEC. Following the filing of a definitive proxy statement

with the SEC, HeartSciences will mail the definitive proxy statement and a proxy card to each shareholder entitled to vote at the special

meeting relating to the Proposed Transaction. INVESTORS AND SHAREHOLDERS OF HEARTSCIENCES ARE URGED TO READ THESE MATERIALS (INCLUDING

ANY AMENDMENTS OR SUPPLEMENTS THERETO) AND ANY OTHER RELEVANT DOCUMENTS IN CONNECTION WITH THE PROPOSED TRANSACTION THAT HEARTSCIENCES

HAS FILED OR MAY FILE WITH THE SEC WHEN THEY BECOME AVAILABLE BECAUSE THEY CONTAIN IMPORTANT INFORMATION ABOUT HEARTSCIENCES AND THE PROPOSED

TRANSACTION. COMMUNICATIONS THAT DO NOT CONTAIN ALL THE INFORMATION THAT SHOULD BE CONSIDERED CONCERNING THE PROPOSED TRANSACTION AND

RELATED MATTERS ARE NOT INTENDED TO PROVIDE THE BASIS FOR ANY INVESTMENT DECISION OR ANY OTHER DECISION IN RESPECT OF SUCH MATTERS. The

preliminary proxy statement, the definitive proxy statement and other relevant materials in connection with the Proposed Transaction (when

they become available), and any other documents filed by HeartSciences with the SEC, may be obtained free of charge at the SEC’s

website at www.sec.gov. In addition, investors and shareholders may obtain free copies of the documents filed with the SEC by sending

a request to the HeartSciences Investor Relations Department at investorrelations@heartsciences.com.

Participants in the Solicitation

HeartSciences and Fortitude, their respective directors and executive

officers, and certain executive officers of Digital Currency Group, Inc., the parent company of Fortitude, may be deemed to be participants

in the solicitation of proxies from HeartSciences’ shareholders with respect to the Proposed Transaction. Information regarding

the identity of the potential participants, and their direct or indirect interests in the Proposed Transaction, by security holdings or

otherwise, is set forth in the preliminary proxy statement and other materials filed or that may be filed with the SEC in connection with

the Proposed Transaction.

No Offer or Solicitation

Any information contained herein is not intended to and does not constitute,

or form part of, an offer, invitation or the solicitation of an offer or invitation to purchase, otherwise acquire, subscribe for, sell

or otherwise dispose of any securities, or the solicitation of any vote or approval in any jurisdiction, pursuant to the Proposed Transaction

or otherwise, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in contravention of applicable law.

The Proposed Transaction will be implemented solely pursuant to the terms and conditions of the merger agreement, which contain the full

terms and conditions of the Proposed Transaction.

Investor Relations and Media Contacts:

HeartSciences

Integrous Communications

Mark Komonoski

Phone: 877-255-8483

Email: mkomonoski@integcom.us

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 8

v3.26.3

Cover

Sep. 15, 2026

Document Type

8-K

Amendment Flag

false

Document Period End Date

Sep. 15, 2026

Entity File Number

001-41422

Entity Registrant Name

HEARTSCIENCES INC.

Entity Central Index Key

0001468492

Entity Tax Identification Number

26-1344466

Entity Incorporation, State or Country Code

Entity Address, Address Line One

550 Reserve Street

Entity Address, Address Line Two

Suite 360

Entity Address, City or Town

Southlake

Entity Address, State or Province

Entity Address, Postal Zip Code

76092

City Area Code

682

Local Phone Number

237-7781

Written Communications

false

Soliciting Material

true

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Entity Emerging Growth Company

true

Elected Not To Use the Extended Transition Period

false

Common Stock [Member]

Title of 12(b) Security

Common Stock

Trading Symbol

HSCS

Security Exchange Name

NASDAQ

Warrants

Title of 12(b) Security

Warrants

Trading Symbol

HSCSW

Security Exchange Name

NASDAQ

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 7A

-Section B

-Subsection 2

+ Details

Name:

dei_EntityExTransitionPeriod

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Details

Name:

us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember

Namespace Prefix:

Data Type:

Balance Type:

Period Type:

- Details

Name:

us-gaap_StatementClassOfStockAxis=HSCSW_WarrantsMember

Namespace Prefix:

Data Type:

Balance Type:

Period Type: